Download
kyoto n.
Skip this Video
Loading SlideShow in 5 Seconds..
KYOTO PowerPoint Presentation

KYOTO

163 Vues Download Presentation
Télécharger la présentation

KYOTO

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. KYOTO BP at follow-up: 133/76 mm Hg in both groups Composite CV events: 5.5% with valsartan vs. 10.2% with usual therapy Stroke/TIA: 1.5% vs. 3% Angina: 1.5% vs. 2.9% (p = 0.01) New-onset DM: 5.2% vs. 7.7% (p = 0.028) Trial design: Hypertensive Japanese patients with one or more CV risk factors were randomized to valsartan titrated to 160 mg daily (n = 1,517) vs. usual therapy without an ACE-I or an ARB (n = 1,514). Results (p < 0.001) (p = 0.015) % Conclusions • Among hypertensive Japanese patients with additional CV risk factors, the use of valsartan beneficial • Valsartan associated with a reduction in composite CV events, which was driven by fewer strokes/TIA and angina Composite CV events Stroke Valsartan Usual therapy Sawada T, et al. Eur Heart J 2009;Aug 31:[Epub]